21:53 , Jan 8, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor mutations on NSD1 or NSD2 could help predict survival in laryngeal cancer. In 179 patients, the absence of mutations on NSD1 or NSD2 in tumor samples was associated with poor overall survival....
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
01:37 , Apr 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Patient sample, cell culture and mouse studies suggest inhibiting WHSC1 could help treat metastatic prostate cancer. In patients, levels of WHSC1 were higher in metastatic tumor samples than in samples from primary...
07:00 , Jul 31, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Benjamin Boettner, Associate Editor, and Chris Cain, Michael J. Haas and Kai-Jye Lou, Senior Writers  Quantitative boost for CSHL The Simons Foundation has donated $50 million to Cold Spring Harbor Laboratory to establish the Simons Center for...
07:00 , May 15, 2014 |  BC Innovations  |  Cover Story

Chromatin's rising tide

To capitalize on the full range of possible chromatin targets in and beyond oncology, industry and academia will need to delve deeper into how chromatin regulation is altered in disease, create tools that can reliably...
07:00 , Oct 17, 2013 |  BC Innovations  |  Strategy

Clinical takeoff for new epigenetic targets

There is little doubt that 2014 will be a banner year for next-generation epigenetics companies, with key clinical data expected for next-generation drugs and first-generation candidates that target new epigenetic regulators. But the big biotech...
07:00 , Oct 10, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Multiple myeloma (MM) Nuclear SET domain-containing protein 2 (NSD2; MMSET; WHSC1) Mouse and cell culture studies suggest...
07:00 , Oct 10, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Mass spectrometry profiling of histone modifications Mass spectrometry profiling of histone modifications could be used to discover new...
07:00 , Oct 10, 2013 |  BC Innovations  |  Cover Story

NSD2 momentum

Although NSD2 has been genetically linked to multiple myeloma for more than 15 years, drug discovery efforts against the target have lagged behind other histone methyltransferases including DOT1L and EZH2. Now, a Novartis Institutes for...